Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
Utility of Fibroscan XL to assess the severity of non-alcoholic fatty liver disease in patients undergoing bariatric surgery | Scientific Reports
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint | Modern Pathology
A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery | Scientific Reports
Frontiers | Validation of Controlled Attenuation Parameter Measured by FibroScan as a Novel Surrogate Marker for the Evaluation of Metabolic Derangement
FibroScan - Because liver health matters
Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis - eClinicalMedicine
Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease | Metrics - Cureus
Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
Diagnostics | Free Full-Text | Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area
PDF) FibroScan-AST Score Predicts 30-Day Mortality or Need for Mechanical Ventilation among Patients Hospitalized with COVID-19
Presentación de PowerPoint
FibroScan - Because liver health matters
Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Pa
JKMS :: Journal of Korean Medical Science
Clinical assessment and management of liver fibrosis in non-alcoholic fatty liver disease
How Good Are Controlled Attenuation Parameter Scores from Fibroscan to Assess Steatosis, NASH, and Fibrosis? | SpringerLink
Prognostic impact of liver fibrosis and steatosis by transient elastography for cardiovascular and mortality outcomes in individuals with nonalcoholic fatty liver disease and type 2 diabetes: the Rio de Janeiro Cohort Study
Diagnostics | Free Full-Text | Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan
CAP cutoff values for the diagnosis of steatosis grades ≥S1, ≥S2, and ≥S3 | Download Table
